Latest news with #Bruker
Yahoo
11-06-2025
- Business
- Yahoo
BRKR Q1 Earnings Call: Tariffs and Funding Headwinds Offset by Product Innovation and Cost Actions
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 11% year on year to $801.4 million. The company's full-year revenue guidance of $3.52 billion at the midpoint came in 0.9% above analysts' estimates. Its non-GAAP profit of $0.47 per share was 5.9% above analysts' consensus estimates. Is now the time to buy BRKR? Find out in our full research report (it's free). Revenue: $801.4 million vs analyst estimates of $768.5 million (11% year-on-year growth, 4.3% beat) Adjusted EPS: $0.47 vs analyst estimates of $0.44 (5.9% beat) The company slightly lifted its revenue guidance for the full year to $3.52 billion at the midpoint from $3.51 billion Management lowered its full-year Adjusted EPS guidance to $2.44 at the midpoint, a 9.5% decrease Operating Margin: 4%, down from 9% in the same quarter last year Organic Revenue rose 2.9% year on year (1.6% in the same quarter last year) Market Capitalization: $6.16 billion Bruker's first quarter results reflected both the company's diversified customer base and the impact of recent acquisitions. CEO Frank Laukien highlighted that biopharma demand strengthened, and the Bruker Scientific Instruments segment achieved 5.1% organic growth, despite declining U.S. and China academic/government orders. Laukien noted that 'our teams executed very well under significant uncertainties in key markets,' and credited new product launches in spatial biology and molecular diagnostics for supporting growth. The company's BioSpin and CALID groups benefited from robust research and diagnostics activity, but the BEST segment saw a decline due to weaker MRI superconductor demand and tough comparisons from last year. Management remained cautious about the sustainability of academic/government funding, emphasizing that delayed China stimulus and new tariffs weighed on segment performance. Looking ahead, Bruker's updated guidance reflects both ongoing challenges and mitigation strategies. CEO Frank Laukien explained that U.S. policy changes and tariffs are expected to create a $100 million gross revenue headwind this year, mostly from academic/government market pressures. At the same time, Laukien outlined actions to offset these impacts, including pricing adjustments, supply chain reengineering, and cost management. CFO Gerald Herman added that mitigation efforts should cover more than half of the operating profit headwind in 2025, with full offset expected by 2026. Management remains focused on product innovation and international growth, while acknowledging that further clarity on U.S. federal research policy and global tariffs will be critical for medium-term outlooks. Management attributed first quarter growth to biopharma demand, recent acquisitions, and new product launches, but acknowledged that academic/government funding reductions and tariffs are creating significant headwinds for certain segments. Biopharma momentum: Bruker saw continued improvement in biopharma demand, with CEO Frank Laukien stating that "biopharma has been increasing from a weak base last year" and is now supported by a broader set of tools, including spatial biology and automation platforms. This trend helped offset challenges in the academic/government sector. Academic/government weakness: The company experienced a notable decline in U.S. academic and government (ACA/GOV) orders, with Laukien estimating a 20-25% revenue drop for this market in 2025. Management reported delays but not cancellations so far, and expressed uncertainty about when NIH and NSF funding would stabilize. Impact of tariffs and policy: Bruker quantified a $100 million gross revenue headwind from U.S. federal funding changes, lower China stimulus, and new import tariffs—especially a 125% Chinese tariff on some U.S. exports. CFO Gerald Herman explained that about $90 million of operating profit is at risk before mitigation actions. Recent acquisitions and product launches: The company launched new products in spatial biology, NMR (nuclear magnetic resonance), and molecular diagnostics, while integrating acquisitions like Chemspeed and ELITech. Laukien described these as "meaningful post-genomic innovations" that support growth outside of volatile funding sources. Cost and supply chain actions: To address margin pressures, Bruker is implementing targeted price increases, cost reductions, and supply network changes. Laukien said these efforts should offset more than half of the 2025 headwinds, with the remainder addressed by 2026 through further operational changes. Bruker's outlook for 2025 is shaped by anticipated weakness in academic and government markets, tariff impacts, and the pace of mitigation measures, with product innovation and international expansion as key offsetting factors. Mitigation of margin headwinds: Management expects pricing actions, cost controls, and supply chain reengineering to offset over half of the 2025 operating profit headwind, with benefits accelerating in the second half of the year and fully realized in 2026. Gerald Herman noted that supply chain adjustments and workforce flexibility, especially in Europe, will help manage fixed costs. Product innovation and diversification: Bruker is relying on new launches in spatial biology, molecular diagnostics, and automation to drive demand in biopharma and industrial markets. Laukien emphasized that recent acquisitions and expanded product offerings are helping to reduce reliance on academic/government funding and diversify revenue streams. Academic/government funding and tariffs remain risks: Management cautioned that further declines in U.S. and China academic/government funding, as well as uncertainty around future tariff policies, could continue to pressure results. The company has not assumed any major improvement in China stimulus or U.S. federal research budgets for the remainder of 2025. In the coming quarters, the StockStory team will focus on (1) evidence that cost and supply chain mitigation actions are offsetting margin and revenue headwinds as planned, (2) stabilization or recovery in U.S. and China academic/government funding trends, and (3) continued growth in biopharma and diagnostics segments supported by new product launches. Progress on integrating recent acquisitions and clarity on global tariff policies will also be key indicators. Bruker currently trades at a forward P/E ratio of 14.7×. Should you double down or take your chips? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
Bruker Corporation BRKR recently announced the acquisition of biocrates life sciences ag, a global leader in mass spectrometry (MS)-based quantitative metabolite analysis based in Innsbruck, Austria. However, the financial terms of the deal were not disclosed. The latest development reflects the two companies' shared passion for multiomics technologies. Biocrates has long been focused on supporting and innovating across multiple MS technologies and vendors, and joining Bruker is expected to scale its impact. Since the June 3 announcement, shares of Bruker have risen 4.8%, finishing yesterday's session at $39.21. Multiomics represents the foundation for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. The company can now support customers with a truly integrated multiomics approach through its services, software and kits for high-end proteomics and metabolomics. Accordingly, this should continue to boost the market sentiment surrounding BRKR stock. Bruker has a market capitalization of $5.80 billion. Going by the Zacks Consensus Estimate, the company's 2025 earnings are expected to increase 1.7%. In the trailing four quarters, it delivered an average earnings beat of 0.5%. The acquisition of biocrates further enhances Bruker's MS-based metabolomics solutions. The biocrates kits cover more than 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform integrates advanced sample preparation, metabolite identification and data analysis. Researchers worldwide rely on their flagship kits, such as MxP Quant 1000, to transform metabolic data from diverse tissues and sample types into clearer biomarkers, accelerate drug development and more precise healthcare. Image Source: Zacks Investment Research The acquisition also supports Bruker's expansion into multiomics solutions, including instruments, reagents, software and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys. Per a research report, the global metabolomics services market is estimated to be valued at $3.2 billion in 2025 and expand at a compound annual growth rate (CAGR) of 12.5% through 2032. The market's growth is being led by growing applications of metabolomics in personalized medicines, drug discovery and development, biomarker discovery, nutrigenomics, and other fields such as toxicology and cancer. The rising R&D investments in pharmaceutical and biotechnology companies also contribute. At the 73rd Conference on Mass Spectrometry and Allied Topics, Bruker announced significant advances in ultra-high sensitivity 4D-Proteomics with the introduction of the timsUltra AIP mass spectrometer. The breakthrough Athena Ion Processor technology further enhances the extreme sensitivity of timsTOF UltraPASEF methods for key biological and clinical research problems with very low sample amounts. Over the past three months, Bruker shares have declined 13.9% compared with the industry's 14.3% fall. Bruker currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 44.6% in the past year compared with the industry's 9.6% growth. Its earnings yield of 8.5% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 158% in the past year. Estimates for the company's 2025 earnings per share have jumped 4.3% to 73 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora'sfiscal 2025 earnings per share have increased 1.3% to $15.75 in the past 30 days. Shares of the company have jumped 22.1% in the past year against the industry's 21% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
03-06-2025
- Business
- Business Wire
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. Bruker Applied MS will showcase two significant innovations: the integration of RECIPE's ClinMass ® and ClinDART ® assay kits with Bruker's EVOQ ® DART-TQ⁺ system for TDM and DoA applications, and the launch of the new timsMetabo™ platform for advanced small molecule analysis. These developments support Bruker's goal of delivering practical, high-performance solutions for routine analytical challenges. Bruker's recent majority investment in RECIPE, a renowned manufacturer of diagnostic assays for small molecule analysis used with triple quadrupole mass spectrometers, marks an important step in expanding its capabilities in TDM and DoA analysis. Since the acquisition, Bruker and RECIPE have collaborated to verify the IVDR certified ClinMASS ® kits for use on the EVOQ DART-TQ⁺ system, initially targeting high-priority compound classes. They are not US-FDA approved, but single compounds as controls and calibrators may be a basis in LDT approaches. In parallel, the companies are preparing the launch of RECIPE's ClinDART ® kits, which are designed as high-throughput, chromatography-free assays for the EVOQ DART-TQ⁺ system. These kits enable rapid, cost-efficient analysis with highly reduced solvent consumption, ease of use and increased lab productivity. All ClinDART ® protocols are currently designated for Research Use Only (RUO). Meanwhile, the newly introduced timsMetabo™ platform represents a leap forward in small molecule analysis. Built on Bruker's proprietary trapped ion mobility spectrometry (TIMS) and enhanced with Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP), timsMetabo™ delivers high sensitivity and selectivity for PFAS detection. In early studies, timsMetabo™ identified 40% more low-mass molecules in water samples compared to previous-generation systems. This innovation supports both regulatory compliance and proactive environmental monitoring, with promising applications in toxicology and forensic science. 'The integration of RECIPE's assay expertise with Bruker's DART triple quad instrumentation is a significant advancement for therapeutic drug monitoring,' said Dr. Gernot Wolfram, Managing Director of RECIPE. 'It represents a promising concept with the potential to enable laboratories to adopt high-throughput, chromatography-free workflows that are efficient, robust, and more sustainable. These could dramatically enhance overall lab productivity and make mass spectrometry more accessible and impactful in routine clinical settings.' 'ASMS 2025 marks an important milestone for Bruker Applied MS,' said Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry. 'With the launch of timsMetabo™ and the strategic integration of RECIPE, we are not only expanding our technology portfolio but also redefining what's possible in applied markets. These innovations reflect our commitment to solving real-world analytical challenges in TDM and environmental analysis.' Looking ahead, Bruker Applied MS will continue to develop solutions for PFAS, forensic toxicology, and therapeutic drug monitoring. The timsMetabo™ platform is expected to support future applications involving low-mass drug metabolites and emerging contaminants, while RECIPE's assay pipeline will further enhance Bruker's applied market offerings. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Business Wire
02-06-2025
- Business
- Business Wire
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
BALTIMORE--(BUSINESS WIRE)--At the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows. A. Bruker Introduces the proteoElute Next-Generation Nanoflow LC System for Robust, Ultra-Sensitive Proteomics Workflows with Real-time Monitoring Bruker announces the launch of the proteoElute, a state-of-the-art nanoflow liquid chromatography (LC) system designed for robust and ultra-sensitive multiomics applications. The proteoElute is ideal for single-cell proteomics, immunopeptidomics, microbiome metaproteomics profiling, and many other proteomics methods, ensuring reliable performance even with limited or very complex biological samples. The proteoElute features innovative TwinScape™ technology, which continuously monitors system health in real-time and runs background diagnostics. This proactive approach alerts users to potential issues, providing peace of mind when working with precious samples. Engineered for relentless reliability, the proteoElute includes biocompatible ceramic valves, new porous metal filters, and a proprietary trap column that together enhance robustness, chromatographic performance, and permit sample recovery. The new injector and needle wash system reduces carry-over by up to 3x, a critical advantage for confidently avoiding background signals when analyzing ultra-low input samples. W. Hayes McDonald, Associate Director in the Department of Biochemistry at Vanderbilt University, commented: ' The combination of the new proteoElute UHPLC platform along with updated PepSep Advanced columns and the proteoTrap column allows us the flexibility to perform any state-of-the-art proteomics workflow with highest performance. Its remarkable robustness gives us the confidence to execute all proteomics workflows at scale. ' B. Bruker Introduces PepSep Advanced Columns for Sharper nLC Peaks, Higher Sensitivity and Further Enhanced Peptide and Protein Identifications For highest sensitivity and performance of the proteoElute nLC system, Bruker introduces a new generation of PepSep Advanced nLC columns, engineered for precision, robustness, and speed. The columns deliver sharper peaks and higher-resolution separations for even deeper proteome coverage and consistent performance with challenging biological samples. In benchmark studies, the PepSep Advanced columns demonstrated approximately 20% improvements in peptide IDs and typically 10% improvements in protein IDs. Combined with CaptiveSpray Ionization (CSI) emitters, users can extend column lifetime by simply replacing the emitter—ensuring long-term performance and cost efficiency. PepSep columns provide the reliability and depth needed for analyzing complex tissue digests or low-input samples. Lynn Spruce, the Technical Director at the Children's Hospital of Philadelphia (CHOP-Penn) Proteomic Core Facility, said: 'The new PepSep Advanced columns have proven to be robust, and they consistently deliver reproducible chromatography. They produce sharper, more symmetrical peaks with no observable tailing, resulting typically in 7–8% increases in protein group identifications. Combined with the convenience of interchangeable emitters and reasonable pricing, it has become our go-to nLC column. It's essentially plug-and-play.' About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Yahoo
30-05-2025
- Business
- Yahoo
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass., May 30, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit View source version on Contacts Joe KostkaDirector, Investor RelationsBruker CorporationT: +1 (978) 313-5800E: Sign in to access your portfolio
